Vlasova M A, Moshkovskiĭ S A, Safarova M P, Makarov O V, Archakov A I
Biomed Khim. 2005 Jul-Aug;51(4):367-83.
Ovarian cancer is most common gynecological malignancy which is difficult for early diagnostics. Development of new methods for diagnostics of ovarian cancer, especially, on early stage, is the urgent problem of modern oncology. A general approach to early diagnostics of cancer is a discovery of specific blood disease biomarkers. Ovarian cancer biomarker used in the modern art, CA125, has some drawbacks resulting in extensive research recently directed to this tumor diagnosis. In particular, it was shown the advantage of parallel use of several diagnostic biomarkers instead of the single one. Proteome techniques (two-dimensional electrophoresis, mass-spectrometry methods) in connection to bioinformatics represent a powerful tool for new biomarker discovery. In this respect, the best method of choice is shown to be SELDI-TOF (Surface-enhanced laser desorption/ionization time-of-flight) technique which combines chromatography protein chip application and mass-spectrometry-based detection. In this review, new ovarian biomarker data obtained by proteome methods are summarized.
卵巢癌是最常见的妇科恶性肿瘤，早期诊断困难。开发新的卵巢癌诊断方法，尤其是早期诊断方法，是现代肿瘤学的紧迫问题。癌症早期诊断的一般方法是发现特定的血液疾病生物标志物。现代医学中使用的卵巢癌生物标志物CA125存在一些缺点，导致最近针对该肿瘤诊断进行了广泛研究。特别是，已显示出同时使用几种诊断生物标志物而非单一生物标志物的优势。蛋白质组技术（二维电泳、质谱方法）与生物信息学相结合是发现新生物标志物的有力工具。在这方面，已表明最佳选择方法是SELDI-TOF（表面增强激光解吸/电离飞行时间）技术，该技术结合了色谱蛋白芯片应用和基于质谱的检测。在本综述中，总结了通过蛋白质组方法获得的新的卵巢生物标志物数据。
